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The effect of oncoplastic reduction on the incidence of post-operative
lymphedema in breast cancer patients undergoing lumpectomy
Sanjay Rama, MD1, Jenna Luker, MD1, Kelley Park, BS1, Renee Barry, MD1, Saheli Ghosh, BS1, Simeng Zhu, MD3, Cara Cannella, MS2 , Yalei Chen, PhD2,
Jessica Bensenhaver, MD1, Eleanor Walker, MD3, Kenneth Levin, MD3, Dunya Atisha, MD4 and Maristella Evangelista, MD4
1Department of Surgical Oncology, 2Department of Public Health Sciences, 3Department of Radiation Oncology, 4Department of Plastic Surgery,
Henry Ford Health System, MI, Detroit

Purpose
- In breast cancer patients with macromastia, breast
conservation surgery (BCS) followed by radiation
therapy (RT) may be associated with a different
complication profile than those without
macromastia.
- Oncoplastic reduction mammoplasty (ORM) aims to
reduce breast volume while excising the tumor bed
and its margins.
- Since breast volume was found to be a risk factor
for chronic breast lymphedema, this study was
performed to determine the impact of ORM on
chronic breast lymphedema as well as other
complications compared to BCS without ORM.

Material & Methods
- We performed a retrospective chart review on
patients who underwent lumpectomy with RT from
2014 to 2018.
- Chronic breast lymphedema (CBL) was defined as
swelling that persisted >1 year post-RT.
- Breast volumes (BV) were determined by
contoured breast volumes or, if unavailable,
estimated by the 95% isodose volumes from the RT
treatment planning system.
- Univariate analysis was used to evaluate patient
factors and treatment outcomes in women with BV
≥1300 cc compared to <1300 cc.
- These same analysis was performed in women
who underwent ORM vs. BCS alone.
- Regression analysis was used to:
- Evaluate factors associated with ≥1
complication
- Identify factors associated with the
development of CBL

Results

Results

- The total population included 1173 patients:
- 1122 (95.7%) underwent BCS alone without ORM
- 51 (4.3%) underwent ORM
- 733 (62.5%) had a BV <1300 cc
- 440 (37.5%) had BV ≥1300 cc
- Multivariate regression analysis demonstrated that
compared to patients with BV < 1300 cc, patients
with BV ≥1300 cc had:
- Higher BMI (OR=1.200, P<0.001)
- Increased risk of CBL (OR=2.127, P=0.024)
- Decreased risk of grade 2 radiation dermatitis
(OR=0.457, P=0.002)

Logistic Regression:
Patient Factors and Complications in Women with
Breast Volumes ≥ 1300
variable

OR (95% CI)

p-value

age

0.99 (0.977-1.006)

0.241

race (black vs. white)

1.18 (0.871-1.598)

0.285

race (other vs. white)

1.17 (0.477-2.871)

0.731

BMI

1.20 (1.168-1.234)

<0.001

hx of diabetes

1.10 (0.794-1.532)

0.559

hx of hypertension

0.99 (0.695-1.407)

0.951

size of lumpectomy specimen

1.00 (1.000-1.001)

0.097

grade 2 radiation dermatitis

0.46 (0.281-0.742)

0.002

grade 3 radiation dermatitis

0.56 (0.285-1.095)

0.090

post-op breast lymphedema >1 year 2.13 (1.102-4.104)

0.024

Logistic Regression:
Patient Factors and Complications in Women
with ORM
variable

OR (95% CI)

p-value

BMI

1.016 (0.976-1.058)

0.441

concurrent ALND procedure

1.239 (0.511-3.004)

0.635

post-op wound dehiscence

12.43 (4.398-35.143) <0.001

post-op hematoma

5.93 (2.375-14.823)

<0.001

post-op seroma

0.20 (0.086-0.468)

<0.001

post-op breast lymphedema >1 year

1.221 (0.408-3.654)

0.721

- ORM was associated with the following outcomes:
- Increased risk of hematoma
(OR=5.93, P<0.001)
- Increased risk of wound dehiscence
(OR=12.43, P<0.001)
- Decreased risk of seroma
(OR=0.20, P<0.001)
- No change in risk for chronic breast lymphedema
- No significant difference in hypofractionated radiation frequency
(76.5% of ORM patients, 72.9% of BCS alone patients, P=0.632)
- No significant difference in boost dose radiation usage
(90.2% of ORM patients, 93.8% of BCS alone patients, P=0.376)

Conclusion
Our data demonstrates that patients with breast
volumes ≥1300 cc were two times more likely to
develop CBL. Although patients with ORM had an
increased risk for surgical site complications, the ORM
procedure may have mitigated their risk for CBL. ORM
should be considered at the time of BCS in women
with macromastia to reduce their future risk of CBL as
there is no cure for this disease.

